论文部分内容阅读
目的探讨多西紫杉醇联合顺铂化疗同步放疗治疗局部晚期非小细胞肺癌的临床疗效。方法我院治疗的非小细胞肺癌患者110例,随机分成观察组和对照组各55例。观察组患者均给予多西紫杉醇联合顺铂化疗同步放疗治疗,对照组患者均给予放化疗序贯治疗。结果观察组患者的临床总有效率明显高于对照组患者(P<0.05);局部控制情况明显优于对照组患者(P<0.05);1年生存率明显高于对照组患者(P<0.05);不良反应发生率明显高于对照组患者(P<0.05)。结论多西紫杉醇联合顺铂化疗同步放疗治疗局部晚期非小细胞肺癌可以有效的提高治疗效果,同时也增加患者的不良反应发生率,但患者可以耐受,值得临床推广。
Objective To investigate the clinical efficacy of docetaxel plus cisplatin combined with concurrent radiotherapy in the treatment of locally advanced non-small cell lung cancer. Methods 110 patients with non-small cell lung cancer treated in our hospital were randomly divided into observation group and control group, 55 cases each. Patients in the observation group were treated with docetaxel and cisplatin combined with concurrent radiotherapy, and patients in the control group were treated with sequential chemotherapy and radiotherapy. Results The total clinical effective rate in the observation group was significantly higher than that in the control group (P <0.05). The local control was significantly better than that in the control group (P <0.05). The 1-year survival rate was significantly higher than that in the control group ). The incidence of adverse reactions was significantly higher than that of the control group (P <0.05). Conclusions Combination of docetaxel and cisplatin combined with concurrent radiotherapy for locally advanced non-small cell lung cancer can effectively improve the therapeutic effect, but also increase the incidence of adverse reactions in patients, but patients can tolerate, worthy of clinical promotion.